Adding Checkpoint Inhibition in Trastuzumab-Resistant HER2+ Breast Cancer

An early-phase trial tested the combination of pembrolizumab with trastuzumab in patients with PD-L1–positive, trastuzumab-resistant, advanced HER2+ breast cancer.

Lascia un commento